Navigation Links
Vion Reports 2008 Third Quarter and Nine-Month Results

Quarterly Conference Call to be Held on Thursday November 6 at 8:30 a.m.

NEW HAVEN, Conn., Nov. 3 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the three-month and nine-month periods ended September 30, 2008.

The Company reported a net loss of $6.8 million, or $0.92 per share, for the three-month period ended September 30, 2008, compared to a net loss of $9.0 million, or $1.33 per share, for the same period in 2007. Weighted-average common shares outstanding for the three months ended September 30, 2008 and 2007 were 7.4 million and 6.8 million, respectively.

Operating expenses were reduced by $3.0 million from $8.6 million in the third quarter of 2007 to $5.6 million in the comparable quarter in 2008. Interest expense for the three months ended September 30, 2008 and 2007 was $1.5 million and $1.4 million, respectively. Interest income for the three months ended September 30, 2008 and 2007 was $224,000 and $938,000, respectively.

For the nine-month period ended September 30, 2008, the net loss was $22.9 million, or $3.12 per share, compared to a net loss of $25.8 million, or $3.87 per share, for the same period in 2007. Weighted-average common shares outstanding for the nine months ended September 30, 2008 and 2007 were 7.4 million and 6.7 million, respectively.

Operating expenses were reduced by $5.7 million, from $25.1 million for the nine-month period in 2007, to $19.4 million in the comparable period in 2008. Interest expense related to the Company's Convertible Senior Notes issued in February 2007 increased by $887,000 over the prior year. Interest income for the first nine months of 2008 decreased by $1.6 million over the comparable 2007 period.

The Company reported ending the quarter with $42.8 million in cash and cash equivalents, sufficient to fund its operations through the fourth quarter of 2009 based on the current operating plan.

Alan Kessman, Chief Executive Officer, commented, "We continue to focus on the preparation of the New Drug Application (NDA) for our lead anticancer agent laromustine (Cloretazine, VNP40101M). The NDA filing will be based on our two Phase II trials in elderly patients with acute myelogenous leukemia. Our plan is to file this NDA in early 2009."

Third Quarter Conference Call

The Company announced that it would hold a conference call on Thursday, November 6, 2008 to discuss its 2008 third quarter financial results. The call will begin at 8:30 a.m. Eastern Time.

To participate in the conference call, please dial (800) 831-6270 in the U.S. ((617) 213-8858 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 85439318.

An audio webcast of the call will be accessible at Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 37383579. The replay will be available through Thursday, November 20, 2008.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R), VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of laromustine (Cloretazine(R), VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly laromustine (Cloretazine,VNP40101M), delays in the regulatory approval process or delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended June 30, 2008. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


(A Development Stage Company)



Three Months Ended Nine Months Ended

September 30, September 30,

(In thousands, except

per share data) 2008 2007 2008 2007

Technology license fee

revenue $8 $6 $35 $16

Operating expenses:

Clinical trials 2,060 3,490 7,867 10,781

Other research and

development 1,620 2,786 5,892 7,898

Total research and

development 3,680 6,276 13,759 18,679

Marketing, general and

administrative 1,872 2,279 5,655 6,387

Total operating expenses 5,552 8,555 19,414 25,066

Loss from operations (5,544) (8,549) (19,379) (25,050)

Interest income 224 938 991 2,603

Interest expense (1,521) (1,423) (4,539) (3,652)

Other expense, net (3) -- (15) (4)

Loss before income taxes (6,844) (9,034) (22,942) (26,103)

Income tax provision

(benefit) -- 3 -- (269)

Net loss ($6,844) ($9,037) ($22,942) ($25,834)

Basic and diluted loss

per share(1) ($0.92) ($1.33) ($3.12) ($3.87)

Weighted-average number of

shares of common stock

outstanding(1) 7,449 6,774 7,355 6,683

(1) Adjusted for all periods presented to reflect the Company's one-for-

ten reverse stock split effected February 20, 2008.



Sept 30, Dec. 31,

(In thousands) 2008 2007

Cash and cash equivalents $42,755 $61,067

Total assets 44,216 63,195

Convertible senior notes 55,139 54,275

Total liabilities 61,629 61,988

Shareholders' (deficit) equity (17,413) 1,207

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008
2. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
3. NxStage Reports Third Quarter 2008 Financial Results
4. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
5. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. Nuvelo Reports Third Quarter 2008 Financial Results
9. Reports Third Quarter 2008 Results
10. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
11. Palomar Medical Reports Financial Results for Third Quarter 2008
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
Breaking Medicine Technology: